Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients

Eltorky, Hagar ; AbdelMageed, Manar ; Ismail, Hager ; Zahran, Faten ; Guirgis, Adel ; Olsson, Lina ; Lindmark, Gudrun LU ; Hammarström, Marie Louise ; Hammarström, Sten and Sitohy, Basel (2024) In Frontiers in Oncology 14.
Abstract

Introduction: The aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16. Methods: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses. Results: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further... (More)

Introduction: The aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16. Methods: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses. Results: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further division was achieved by LGR6 analysis. LGR6(+) patients had a very poor prognosis. LGR6 also identified a small number of CEA(-), TNM stage I patients who relapsed suggesting stem cell origin of these tumors. LGR6 and LGR5 levels correlated strongly in lymph nodes of stage I and IV patients but not in stage II patients, suggesting that these stem cell markers are differentially regulated. Conclusion: This study highlights LGR6 as a useful prognostic biomarker independently and in combination with CEA, CXCL16 or LGR5 identifying different risk groups.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
cancer stem cells, CEA, colon cancer, CXCL16, LGR5, LGR6, qRT-PCR, regional lymph nodes
in
Frontiers in Oncology
volume
14
article number
1393075
publisher
Frontiers Media S. A.
external identifiers
  • pmid:38715790
  • scopus:85192206246
ISSN
2234-943X
DOI
10.3389/fonc.2024.1393075
language
English
LU publication?
yes
id
c39e5e21-bd52-448b-a63d-81abec8b0500
date added to LUP
2024-05-16 14:22:14
date last changed
2024-05-17 03:00:06
@article{c39e5e21-bd52-448b-a63d-81abec8b0500,
  abstract     = {{<p>Introduction: The aim was to investigate whether the stem cell marker LGR6 has prognostic value in colon cancer, alone or in combination with the prognostic biomarkers CEA and CXCL16. Methods: LGR6 mRNA levels were determined in 370 half lymph nodes of 121 colon cancer patients. Ability to predict relapse after curative surgery was estimated by Kaplan-Meier survival model and Cox regression analyses. Results: Patients with high LGR6 levels [LGR6(+)] had a decreased mean survival time of 11 months at 5-year follow-up and 47 months at 12-year follow-up, respectively, with hazard ratios of 3.2 and 2.8. LGR6 mRNA analysis added prognostic value to CEA and CXCL16 mRNA analysis. In the poor prognosis groups CEA(+) and CXCL16(+), further division was achieved by LGR6 analysis. LGR6(+) patients had a very poor prognosis. LGR6 also identified a small number of CEA(-), TNM stage I patients who relapsed suggesting stem cell origin of these tumors. LGR6 and LGR5 levels correlated strongly in lymph nodes of stage I and IV patients but not in stage II patients, suggesting that these stem cell markers are differentially regulated. Conclusion: This study highlights LGR6 as a useful prognostic biomarker independently and in combination with CEA, CXCL16 or LGR5 identifying different risk groups.</p>}},
  author       = {{Eltorky, Hagar and AbdelMageed, Manar and Ismail, Hager and Zahran, Faten and Guirgis, Adel and Olsson, Lina and Lindmark, Gudrun and Hammarström, Marie Louise and Hammarström, Sten and Sitohy, Basel}},
  issn         = {{2234-943X}},
  keywords     = {{cancer stem cells; CEA; colon cancer; CXCL16; LGR5; LGR6; qRT-PCR; regional lymph nodes}},
  language     = {{eng}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Oncology}},
  title        = {{LGR6 is a prognostic biomarker for less differentiated tumors in lymph nodes of colon cancer patients}},
  url          = {{http://dx.doi.org/10.3389/fonc.2024.1393075}},
  doi          = {{10.3389/fonc.2024.1393075}},
  volume       = {{14}},
  year         = {{2024}},
}